A study has found that sirolimus-coated balloons vs thin drug-eluting stents in in-stent restenosis show similar favorable clinical outcomes.

Novel drug-coated balloons (DCB) did not outshine standard treatment with second generation drug-eluting stents (DES ...

In PCI, a catheter is passed usually from the femoral artery in the groin up to the heart and into the small ... blockage after placement. These drug-eluting stents yield a marked reduction ...

PRNewswire New Delhi [India]1 Translumina was incorporated in 2011 as a sales marketing company specialising in coronary ...

Undergoing percutaneous coronary intervention (PCI) for narrowed arteries with a novel bioadaptor is at least as effective as ...

Among patients undergoing non-cardiac surgery more than 1 year after coronary drug-eluting ... to guide stent implantation during percutaneous coronary intervention (PCI) in heart disease patients ...

The DynamX Bioadaptor device was noninferior to DES for TLF overall, but a landmark analysis reveals a potential strength.

As of 2023, drug-eluting stents hold the largest market share due ... significantly drives the demand for coronary stents.

Undergoing percutaneous coronary intervention (PCI) for narrowed arteries with a novel bioadaptor is at least as effective as a contemporary drug-eluting stent (DES) with regard to target lesion ...

The vascular stents market is anticipated to grow from USD 11.4 billion in 2024 to USD 15.6 billion by 2029, with a CAGR of 6.5%. This growth ...